Skip to main content

Table 2 Hazard ratios for specific breast cancer outcomes by BMI groups in patients with chemotherapy or hormonal plus chemotherapy (N=1049)

From: Obesity and breast cancer outcomes in chemotherapy patients in New Zealand – a population-based cohort study

Outcome Follow-up period BMI (kg/m2) No of events Crude HR (95% CI) Adjusted HR (95% CI)
Breast cancer specific death 0-10 yrs <21 (N=81) 43 1.70 (0.99, 2.91) 1.13 (0.60, 2.14)
21-24 (N=250) 88 1.00 1.00
25-29 (N=349) 107 0.99 (0.66, 1.47) 0.96 (0.61, 1.51)
30-34 (N=225) 67 1.24 (0.82, 1.88) 0.98 (0.62, 1.54)
35+ (N=144) 49 1.31 (0.81, 2.12) 0.99 (0.57, 1.71)
Whole study period <21 44 1.66 (0.97, 2.84) 1.11 (0.59, 2.09)
21-24 91 1.00 1.00
25-29 110 0.98 (0.66, 1.46) 0.95 (0.61, 1.50)
30-34 67 1.21 (0.80, 1.83) 0.96 (0.62, 1.50)
35+ 49 1.28 (0.79, 2.07) 0.96 (0.56, 1.67)
Overall mortality 0-10 yrs <21 67 1.64 (0.98, 2.73) 1.12 (0.61, 2.05)
21-24 122 1.00 1.00
25-29 153 1.01 (0.69, 1.46) 0.92 (0.60, 1.41)
30-34 93 1.17 (0.79, 1.73) 0.88 (0.57, 1.34)
35+ 65 1.37 (0.88, 2.16) 1.05 (0.64, 1.73)
Whole study period <21 70 1.49 (0.89, 2.51) 1.04 (0.57, 1.90)
21-24 130 1.00 1.00
25-29 163 0.97 (0.68, 1.40) 0.87 (0.57, 1.32)
30-34 100 1.18 (0.81, 1.72) 0.89 (0.59, 1.33)
35+ 69 1.36 (0.87, 2.10) 1.03 (0.63, 1.67)
Death from other/unknown causes 0-10 <21 24 1.08 (0.22, 5.34) 1.44 (0.21, 9.97)
21-24 34 1.00 1.00
25-29 46 1.15 (0.41, 3.25) 1.11 (0.33, 3.72)
30-34 26 0.74 (0.21, 2.58) 0.74 (0.21, 2.67)
35+ 16 1.64 (0.50, 5.43) 1.55 (0.34, 7.18)
Whole study period <21 26 0.70 (0.14, 3.45) 1.01 (0.19, 5.45)
21-24 39 1.00 1.00
25-29 53 0.98 (0.39, 2.43) 0.78 (0.27, 2.29)
30-34 33 1.04 (0.40, 2.72) 1.15 (0.42, 3.11)
35+ 20 1.56 (0.54, 4.51) 1.42 (0.40, 5.01)
Loco-regional recurrence 0-5 <21 (N=81) 13 1.04 (0.22, 4.98) 1.24 (0.20, 7.64)
21-24 (N=250) 22 1.00 1.00
25-29 (N=349) 23 0.87 (0.32, 2.40) 1.13 (0.34, 3.73)
30-34 (N=225) 27 0.88 (0.28, 2.77) 1.38 (0.36, 5.29)
35+ (N=144) 11 0.60 (0.12, 2.87) 1.12 (0.16, 7.84)
Whole study period <21 17 1.58 (0.42, 6.02) 2.08 (0.42, 10.23)
21-24 25 1.00 1.00
25-29 25 1.11 (0.42, 2.93) 1.26 (0.41, 3.87)
30-34 28 1.10 (0.37, 3.28) 1.58 (0.44, 5.63)
35+ 12 0.63 (0.13, 3.04) 1.17 (0.19, 7.21)
Distant metastasis 0-5 <21 43 1.74 (0.66, 4.54) 1.44 (0.51, 4.03)
21-24 90 1.00 1.00
25-29 103 1.13 (0.57, 2.24) 0.89 (0.44, 1.80)
30-34 65 1.20 (0.56, 2.55) 1.17 (0.51, 2.67)
35+ 62 1.62 (0.72, 3.64) 1.69 (0.69, 4.11)
Whole study period <21 46 1.62 (0.67, 3.93) 1.32 (0.52, 3.37)
21-24 103 1.00 1.00
25-29 127 1.38 (0.76, 2.53) 1.05 (0.56, 1.94)
30-34 87 1.50 (0.77, 2.90) 1.23 (0.61, 2.49)
35+ 70 1.73 (0.82, 3.63) 1.33 (0.61, 2.91)
  1. ‘Adjusted’ results from Cox regression model including BMI and ethnicity, menopausal status, age, social deprivation, urban-rural status, mode of diagnosis (screening vs. symptomatic), year of diagnosis, stage, grade, histology, hormone receptor status (ER and PR), local treatment (surgery and radiotherapy), systemic treatment (chemotherapy, hormonal therapy and biological treatment), treatment facility (public vs. private), comorbidity index